Novartis A Buy At Chardan By: Benzinga via Benzinga September 20, 2016 at 10:15 AM EDT Chardan Capital’s Gbola Amusa believes Novartis AG (ADR) (NYSE: NVS) has the “potential for excess shareholder returns over ... Read More >> Related Stocks: Novartis Ag ADR